Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C22H27NO.ClH |
| Molecular Weight | 357.917 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC1=CC=CC=C1C(O)(C2CN3CCC2CC3)C4=CC=CC=C4C
InChI
InChIKey=WCYWFJOJKZCSAJ-UHFFFAOYSA-N
InChI=1S/C22H27NO.ClH/c1-16-7-3-5-9-19(16)22(24,20-10-6-4-8-17(20)2)21-15-23-13-11-18(21)12-14-23;/h3-10,18,21,24H,11-15H2,1-2H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C22H27NO |
| Molecular Weight | 321.4559 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Sequifenadine is H1- and 5HT-serotonine receptor antagonist. It has an anti-histamine effect, not only blocking histamine receptors, but also reducing the content of histamine in tissues by accelerating its destruction by diamine oxidase. Sequifenadine did not demonstrate any significant sedative effect. It has a pronounced and prolonged antipruritic and antiexudative effect. It is indicated for the treatment of allergic rhinitis and conjunctivitis, pollinosis, urticaria, angioedema, allergic pruritic dermatosis, including atopic dermatitis. Adverse effects are: dry mouth, pain in the epigastric region, dyspepsia, increased appetite, headache, sleepiness.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://36i6.info/sehifenadin-sequifenadine/
50-100 mg 2-3 times per day. The course of treatment is 5-15 days.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:57:38 GMT 2025
by
admin
on
Tue Apr 01 16:57:38 GMT 2025
|
| Record UNII |
305T85J01Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000128096
Created by
admin on Tue Apr 01 16:57:38 GMT 2025 , Edited by admin on Tue Apr 01 16:57:38 GMT 2025
|
PRIMARY | |||
|
42552
Created by
admin on Tue Apr 01 16:57:38 GMT 2025 , Edited by admin on Tue Apr 01 16:57:38 GMT 2025
|
PRIMARY | |||
|
305T85J01Y
Created by
admin on Tue Apr 01 16:57:38 GMT 2025 , Edited by admin on Tue Apr 01 16:57:38 GMT 2025
|
PRIMARY | |||
|
DTXSID30973319
Created by
admin on Tue Apr 01 16:57:38 GMT 2025 , Edited by admin on Tue Apr 01 16:57:38 GMT 2025
|
PRIMARY | |||
|
57734-70-0
Created by
admin on Tue Apr 01 16:57:38 GMT 2025 , Edited by admin on Tue Apr 01 16:57:38 GMT 2025
|
PRIMARY | |||
|
SUB34794
Created by
admin on Tue Apr 01 16:57:38 GMT 2025 , Edited by admin on Tue Apr 01 16:57:38 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |